{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T16:52:00Z","timestamp":1743007920764,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":15,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071637852"},{"type":"electronic","value":"9781071637869"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-1-0716-3786-9_13","type":"book-chapter","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T16:03:05Z","timestamp":1710950585000},"page":"129-135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of Nanoparticles\u2019 Effects on Drug-Induced Psoriasis"],"prefix":"10.1007","author":[{"given":"Ankit","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelsea","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Difilippantonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elijah","family":"Edmondson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina A.","family":"Dobrovolskaia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"13_CR1","first-page":"87","volume":"7","author":"DM Balak","year":"2017","unstructured":"Balak DM, Hajdarbegovic E (2017) Drug-induced psoriasis: clinical perspectives. Psoriasis (Auckl) 7:87\u201394","journal-title":"Psoriasis (Auckl)"},{"issue":"10","key":"13_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077159","volume":"8","author":"ZJ Li","year":"2013","unstructured":"Li ZJ, Sohn KC, Choi DK, Shi G, Hong D, Lee HE, Whang KU, Lee YH, Im M, Lee Y, Seo YJ, Kim CD, Lee JH (2013) Roles of TLR7 in activation of NF-\u03baB signaling of keratinocytes by imiquimod. PLoS One 8(10):e77159","journal-title":"PLoS One"},{"issue":"2","key":"13_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11606-016-3900-2","volume":"32","author":"JB Doyon","year":"2017","unstructured":"Doyon JB, Liu KJ, Berman RA (2017) Metoprolol-induced total body erythroderma. J Gen Intern Med 32(2):221\u2013222","journal-title":"J Gen Intern Med"},{"issue":"6","key":"13_CR4","doi-asserted-by":"publisher","first-page":"734","DOI":"10.2340\/00015555-1161","volume":"91","author":"AV Kuznetsov","year":"2011","unstructured":"Kuznetsov AV, Weisenseel P, Flaig MJ, Ruzicka T, Prinz JC (2011) Photoallergic erythroderma due to doxycycline therapy of erythema chronicum migrans. Acta Derm Venereol 91(6):734\u2013736","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"13_CR5","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","volume":"144","author":"JG Krueger","year":"2019","unstructured":"Krueger JG, Wharton KA Jr, Schlitt T, Suprun M, Torene RI, Jiang X, Wang CQ, Fuentes-Duculan J, Hartmann N, Peters T, Koroleva I, Hillenbrand R, Letzkus M, Yu X, Li Y, Glueck A, Hasselberg A, Flannery B, Su\u00e1rez-Fari\u00f1as M, Hueber W (2019) IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J Allergy Clin Immunol 144(3):750\u2013763","journal-title":"J Allergy Clin Immunol"},{"key":"13_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114898","volume":"199","author":"S Alexander","year":"2023","unstructured":"Alexander S, Moghadam MG, Rothenbroker M, Chou LYT (2023) Addressing the in vivo delivery of nucleic-acid nanostructure therapeutics. Adv Drug Deliv Rev 199:114898","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"13_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3390\/ph16040581","volume":"16","author":"H Chopra","year":"2023","unstructured":"Chopra H, Mohanta YK, Rauta PR, Ahmed R, Mahanta S, Mishra PK, Panda P, Rabaan AA, Alshehri AA, Othman B, Alshahrani MA, Alqahtani AS, Al Basha BA, Dhama K (2023) An insight into advances in developing nanotechnology based therapeutics, drug delivery, diagnostics and vaccines: multidimensional applications in tuberculosis disease management. Pharmaceuticals (Basel) 16(4):581","journal-title":"Pharmaceuticals (Basel)"},{"key":"13_CR8","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.2147\/IJN.S406415","volume":"18","author":"SJ Kim","year":"2023","unstructured":"Kim SJ, Puranik N, Yadav D, Jin JO, Lee PCW (2023) Lipid nanocarrier-based drug delivery systems: therapeutic advances in the treatment of lung cancer. Int J Nanomedicine 18:2659\u20132676","journal-title":"Int J Nanomedicine"},{"key":"13_CR9","doi-asserted-by":"publisher","first-page":"114962","DOI":"10.1016\/j.addr.2023.114962","volume":"200","author":"S Puri","year":"2023","unstructured":"Puri S, Mazza M, Roy G, England RM, Zhou L, Nourian S, Anand Subramony J (2023) Evolution of nanomedicine formulations for targeted delivery and controlled release. Adv Drug Deliv Rev 200:114962","journal-title":"Adv Drug Deliv Rev"},{"key":"13_CR10","doi-asserted-by":"publisher","unstructured":"Dadwal N, Kurmi BD, Singh D, Singh A (2023) Recent advancements in novel formulations of anti-psoriatic agents for effective delivery: clinical importance and patent survey. Recent Pat Nanotechnol. https:\/\/doi.org\/10.2174\/1872210517666230601124620. Epub ahead of print. PMID: 37264655","DOI":"10.2174\/1872210517666230601124620"},{"key":"13_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.taap.2018.04.028","volume":"350","author":"A Shah","year":"2018","unstructured":"Shah A, Mankus CI, Vermilya AM, Soheilian F, Clogston JD, Dobrovolskaia MA (2018) Feraheme\u00ae suppresses immune function of human T lymphocytes through mitochondrial damage and mitoROS production. Toxicol Appl Pharmacol 350:52\u201363","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"13_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.33218\/prnano2(1).181218.1","volume":"2","author":"A Shah","year":"2019","unstructured":"Shah A, Cedrone E, Sanders CL, Butcher D, DeFrancesco AM, DeGrange CL, Difilippantonio S, Edmondson EF, Dobrovolskaia MA (2019) The potential utility of iron oxide nanoparticles for the treatment of skin inflammation in a mouse model of psoriasis. Precis Nanomed 2(1):249\u2013255","journal-title":"Precis Nanomed"},{"issue":"10","key":"13_CR13","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1158\/1078-0432.CCR-21-0496","volume":"28","author":"W Chen","year":"2022","unstructured":"Chen W, Bamford RN, Edmondson EF, Waldmann TA (2022) IL15 and anti-PD-1 augment the efficacy of agonistic intratumoral anti-CD40 in a mouse model with multiple TRAMP-C2 tumors. Clin Cancer Res 28(10):2082\u20132093","journal-title":"Clin Cancer Res"},{"key":"13_CR14","unstructured":"USFDA (2023) Guidance for industry: nonclinical evaluation of the immunotoxic potential of pharmaceuticals"},{"issue":"4","key":"13_CR15","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4103\/aca.ACA_94_19","volume":"22","author":"P Mishra","year":"2019","unstructured":"Mishra P, Singh U, Pandey CM, Mishra P, Pandey G (2019) Application of student\u2019s t-test, analysis of variance, and covariance. Ann Card Anaesth 22(4):407\u2013411","journal-title":"Ann Card Anaesth"}],"container-title":["Methods in Molecular Biology","Characterization of Nanoparticles Intended for Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3786-9_13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T16:03:53Z","timestamp":1710950633000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3786-9_13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9781071637852","9781071637869"],"references-count":15,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3786-9_13","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"21 March 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}